Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Authors
Keywords
-
Journal
PLoS Genetics
Volume 15, Issue 12, Pages e1008489
Publisher
Public Library of Science (PLoS)
Online
2019-12-13
DOI
10.1371/journal.pgen.1008489
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
- (2019) Phuong A. Nguyen et al. Nature Communications
- The Post-GWAS Era: From Association to Function
- (2018) Michael D. Gallagher et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
- (2017) Hsin-Pei Shih et al. NATURE REVIEWS DRUG DISCOVERY
- Changing R&D models in research-based pharmaceutical companies
- (2016) Alexander Schuhmacher et al. Journal of Translational Medicine
- Impact of genetically supported target selection on R&D productivity
- (2016) Mark R. Hurle et al. NATURE REVIEWS DRUG DISCOVERY
- The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
- (2016) Jacqueline MacArthur et al. NUCLEIC ACIDS RESEARCH
- A global reference for human genetic variation
- (2015) Richard A. Gibbs et al. NATURE
- The support of human genetic evidence for approved drug indications
- (2015) Matthew R Nelson et al. NATURE GENETICS
- The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
- (2015) et al. SCIENCE
- GWAS and drug targets
- (2014) Chen Cao et al. BMC GENOMICS
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Patterns of regulatory activity across diverse human cell types predict tissue identity, transcription factor binding, and long-range interactions
- (2013) N. C. Sheffield et al. GENOME RESEARCH
- Validating therapeutic targets through human genetics
- (2013) Robert M. Plenge et al. NATURE REVIEWS DRUG DISCOVERY
- The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
- (2013) Danielle Welter et al. NUCLEIC ACIDS RESEARCH
- Protein Replacement Therapies for Rare Diseases: A Breeze for Regulatory Approval?
- (2013) J. A. Gorzelany et al. Science Translational Medicine
- Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes
- (2013) Slavé Petrovski et al. PLoS Genetics
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff
- (2012) Pablo Cingolani et al. FLY
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- (2010) Steven M. Paul et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now